About TORL BioTherapeutics
TORL BioTherapeutics is a company based in Los Angeles (United States) founded in 2019 by Mark Attanasio and Dave Licata.. TORL BioTherapeutics has raised $412.3 million across 3 funding rounds from investors including ARE, TD Securities and Bristol-Myers Squibb. TORL BioTherapeutics offers products and services including TORL-1-23, TORL-2-307, TORL-3-600, and TORL-4-500. TORL BioTherapeutics operates in a competitive market with competitors including Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others.
- Headquarter Los Angeles, United States
- Founders Mark Attanasio, Dave Licata
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Torl Biotherapeutics, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$412.3 M (USD)
in 3 rounds
-
Latest Funding Round
$96 M (USD), Series C
Oct 07, 2025
-
Investors
ARE
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TORL BioTherapeutics
TORL BioTherapeutics offers a comprehensive portfolio of products and services, including TORL-1-23, TORL-2-307, TORL-3-600, and TORL-4-500. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets CLDN6 for treating advanced cancers
Treats CLDN18.2+ solid tumors
Addresses CDH17+ colorectal cancer
Targets DLK1 positive solid tumors
Unlock access to complete
Funding Insights of TORL BioTherapeutics
TORL BioTherapeutics has successfully raised a total of $412.3M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $96 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $96.0M
-
First Round
First Round
(13 Apr 2023)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series C - TORL BioTherapeutics | Valuation |
investors |
|
| Apr, 2024 | Amount | Series B - TORL BioTherapeutics | Valuation |
investors |
|
| Apr, 2023 | Amount | Series B - TORL BioTherapeutics | Valuation | Goldman Sachs Asset Management |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TORL BioTherapeutics
TORL BioTherapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, TD Securities and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are focused on agtech, renewable energy, and transportation sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TORL BioTherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TORL BioTherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Torl Biotherapeutics Comparisons
Competitors of TORL BioTherapeutics
TORL BioTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, MorphoSys and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
ALX Oncology is focused on advancing cancer treatment therapies.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Torl Biotherapeutics
Frequently Asked Questions about TORL BioTherapeutics
When was TORL BioTherapeutics founded?
TORL BioTherapeutics was founded in 2019 and raised its 1st funding round 4 years after it was founded.
Where is TORL BioTherapeutics located?
TORL BioTherapeutics is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Who is the current CEO of TORL BioTherapeutics?
Dave Licata is the current CEO of TORL BioTherapeutics. They have also founded this company.
Is TORL BioTherapeutics a funded company?
TORL BioTherapeutics is a funded company, having raised a total of $412.3M across 3 funding rounds to date. The company's 1st funding round was a Series B of $158M, raised on Apr 13, 2023.
What does TORL BioTherapeutics do?
TORL BioTherapeutics was founded in 2019 and is based in Los Angeles, United States. Antibody-based therapeutics are developed by the company for oncology indications. The lead candidate, TORL-1-23, is a CLDN6-directed antibody-drug conjugate targeted at multiple cancer types. A pipeline of preclinical antibody-drug conjugates and monoclonal antibodies is also advanced in various oncologic areas.
Who are the top competitors of TORL BioTherapeutics?
TORL BioTherapeutics's top competitors include Moderna, BeiGene and Strand Therapeutics.
What products or services does TORL BioTherapeutics offer?
TORL BioTherapeutics offers TORL-1-23, TORL-2-307, TORL-3-600, and TORL-4-500.
Who are TORL BioTherapeutics's investors?
TORL BioTherapeutics has 10 investors. Key investors include ARE, TD Securities, Bristol-Myers Squibb, University of California, and Xontogeny.